Literature DB >> 11756771

Diagnostic Accuracy of Cervical Low-Grade Squamous Intraepithelial Lesions Is Improved With MIB-1 Immunostaining.

Edyta C Pirog1, Rebecca N Baergen, Robert A Soslow, Diane Tam, Amy E DeMattia, Yao-Tseng Chen, Christina Isacson.   

Abstract

There is considerable interobserver variation in the diagnosis of low-grade squamous intraepithelial lesion that involves mature squamous epithelium. Our aim was to evaluate the utility of MIB-1 immunostaining as an adjunct test to increase diagnostic accuracy. Consecutive cervical biopsies originally diagnosed as normal (n = 26) or low-grade squamous intraepithelial lesion (n = 23) were reviewed by three pathologists to obtain a consensus diagnosis. MIB-1 immunostaining was performed, and positive staining was defined as a cluster of at least two stained nuclei in the upper two thirds of the epithelial thickness. Human papillomavirus (HPV) DNA detection was performed using a polymerase chain reaction assay. All cases were subsequently reclassified as low-grade squamous intraepithelial lesion (LSIL) or normal (NL) when two or three of three gold standard criteria were satisfied (LSIL gold standard criteria = consensus diagnosis of LSIL, HPV+, MIB-1+; NL gold standard criteria = consensus diagnosis of NL, HPV-, MIB-1-). Using the gold standard diagnoses, we have identified that 14 normal cases (36%) were originally overdiagnosed as LSIL, and one LSIL case (10%) was originally underdiagnosed as normal. All MIB-1-positive cases were HPV+ and identified as LSIL in the consensus review. All MIB-1-negative cases were NL by gold standard criteria. The sensitivity (1.0) and the specificity (1.0) of MIB-1 staining for identifying LSIL were superior to the sensitivity (0.9) and the specificity (0.8) of HPV testing. In conclusion, MIB-1 is a highly sensitive and specific marker for identifying low-grade squamous intraepithelial lesion and is helpful in verifying the diagnosis of equivocal cases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756771     DOI: 10.1097/00000478-200201000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Cancer of the cervix - from bleak past to bright future; a review, with an emphasis on cancer of the cervix in malaysia.

Authors:  Othman Nor Hayati
Journal:  Malays J Med Sci       Date:  2003-01

2.  p16 Immunohistochemistry Is Not Always Required For Accurate Diagnosis of Grade 2 Squamous Intraepithelial Lesions.

Authors:  Lulu Sun; Lingxin Zhang; Hannah R Krigman; Ian S Hagemann
Journal:  J Low Genit Tract Dis       Date:  2018-04       Impact factor: 1.925

Review 3.  Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers.

Authors:  J P A Baak; A-J Kruse; S J Robboy; E A M Janssen; B van Diermen; I Skaland
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

4.  [Diagnosis and grading of cervical intraepithelial neoplasias].

Authors:  C Rosamilia; G Feichter; A Tzankov; E C Obermann
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

5.  Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection.

Authors:  Eun Ji Nam; Jae Wook Kim; Jong Wook Hong; Hyoung Sun Jang; Sang Yub Lee; Si Young Jang; Dae Woo Lee; Sang Wun Kim; Jae Hoon Kim; Young Tae Kim; Sunghoon Kim; Jong Wook Kim
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

6.  Investigating Diagnostic Problems of CIN1 and CIN2 Associated With High-risk HPV by Combining the Novel Molecular Biomarker PanHPVE4 With P16INK4a.

Authors:  Romy van Baars; Heather Griffin; Zhonglin Wu; Yasmina Jay Soneji; Miekel van de Sandt; Rupali Arora; Jacolien van der Marel; Bram Ter Harmsel; Robert Jach; Krzysztof Okon; Hubert Huras; David Jenkins; Wim Quint; John Doorbar
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.394

Review 7.  Cervical Pre-cancers: Biopsy and Immunohistochemistry.

Authors:  Meherbano Kamal
Journal:  Cytojournal       Date:  2022-06-14       Impact factor: 2.345

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.